F Fuzkk Atlas of the USA
#204Extended selection 101–500

Acrivon Therapeutics

Massachusetts / New England

Oncology / ADC / high-potency

Manufacturing profile

Oncology / ADC / high-potency

Biopharma hub: Massachusetts / New England

Selection basis

The company is placed in positions 101–500 as a manufacturer, biotech, generics, advanced-therapy company or CDMO with practical relevance to the FUZKK utility catalog.

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Representative manufacturing and QC chain

  1. 1Contained dispensing and high-potency handling
  2. 2Chemical synthesis or biologic upstream
  3. 3Purification and formulation
  4. 4HPLC/LC-MS/CE and potency analytics
  5. 5Controlled fill-finish, cleaning and release evidence

Relevant FUZKK packages

United States: national essential medicines QC packageADC / Conjugated Biologics QC SuiteGlobal API & Biosimilars QC Suite

Product/API utilities

ADC Aggregation MonitorADC Drug Antibody Ratio AnalyzerADC Free Payload QuantifierADC Linker Stability ProfilerADCRelease Readiness Checker

Lumex — instrumental QC

System Suitability Parameters Checker

LabEx — laboratory QC

Assay & Impurity HPLC Quality CheckerLC-MS Confirmation Quality CheckerSterility Test Membrane Filtration Quality Checker

Medical Devices — equipment and software lifecycle

Supplier Evaluation CheckerCalibration Status CheckerProcess Validation CheckerChange Control Impact CheckerRequirement Traceability CheckerData Integrity Security Checker

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.

Methodology